BioCurity Pharmaceuticals Inc. offering is now closed and is no longer accepting investments.

INVEST IN BIOCURITY PHARMACEUTICALS INC. TODAY!

Because we believe that fighting cancer is hard enough!

BioCurity is a clinical stage biopharmaceutical company. We are developing our first drug to prevent or mitigate burns to the skin of patients with cancer during radiation therapy. The proposed drugs generated from BioCurity’s proprietary technology have been preclinically tested for multiple cancers including breast, lung, head and neck, prostate and colorectal cancer. The method of administration of the proposed drug includes a topical for the skin to prevent or mitigate skin damage (radiation dermatitis) and an intravenous (IV) formulation for internal tissue protection from radiation damage. We intend to accomplish these goals without impairing the effectiveness of radiation treatment or causing toxic side effects to the cancer patient. We believe our technology can save billions of dollars annually of healthcare dollars used now to treat preventable side effects of radiation therapy.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
BioCurity Pharmaceuticals Inc.

$390,048 Raised

REASONS TO INVEST

Reasons Icon

Our technology may provide cost effective protection for millions of cancer patients every year from burns and other more serious side effects for cancer patients undergoing radiation therapy

Reasons Icon

Seven issued US patents with fully paid license for its technology in the US with a growing portfolio of international patents for our technology when patients are undergoing radiation plus chemotherapy

Reasons Icon

Our team of experts brings over two decades of cancer treatment research, global biotechnology distribution and corporate governance

ABOUT

HEADQUARTERS
110 Front Street, Suite 300
Jupiter, FL 33477

BioCurity is a clinical stage biopharmaceutical company. We are developing our first drug to prevent or mitigate burns to the skin of patients with cancer during radiation therapy. The proposed drugs generated from BioCurity’s proprietary technology have been preclinically tested for multiple cancers including breast, lung, head and neck, prostate and colorectal cancer. The method of administration of the proposed drug includes a topical for the skin to prevent or mitigate skin damage (radiation dermatitis) and an intravenous (IV) formulation for internal tissue protection from radiation damage. We intend to accomplish these goals without impairing the effectiveness of radiation treatment or causing toxic side effects to the cancer patient. We believe our technology can save billions of dollars annually of healthcare dollars used now to treat preventable side effects of radiation therapy.

TEAM

Dr. Cheryl Baker
Dr. Cheryl Baker
Chief Scientific Research Officer, and Director

Cheryl Baker has conducted cancer research for 20 plus years and published more than 45 peer-reviewed manuscripts, book chapters and articles. The proprietary nanoparticle technology supporting BioCurity’s mission was preclinically developed and tested by Cheryl Baker and her research and physician-scientist colleagues at an MD Anderson Cancer Center affiliate in collaboration with researchers at a State University.

Sam Merchant
Sam Merchant
Chairman of the Board of Directors

Sam has 30 Years of Experience, Co-Chairman, 3rd Generation Global Family Office, Extensive Success Growing Companies Globally in Multiple Sectors including, Information-Technology, Healthcare, Bio-Technology, Pharmaceutical, R&D, Manufacturing, Distribution, Commercial Real Estate, Banking and Finance and other sectors. He has been a part of Capital Market Development for over 100 International and Domestic Companies.

Nancy Cass, Esq
Nancy Cass, Esq
Director

Nancy has 20 plus years securities law and transactional law experience with public and private emerging growth and middle market companies. Experienced in examining opportunities for financings, strategic partnerships and other transactions. Interacts with attorneys on transactions, review documents and conducts due diligence with added insight from her legal and securities training.

TERMS

BioCurity Pharmaceuticals Inc.
Overview
PRICE PER SHARE
$4.25
DEADLINE
Jun 30, 2020
VALUATION
$34.02M
AMOUNT RAISED
$390,048
Breakdown
MIN INVESTMENT
$510
MAX INVESTMENT
$106,998
MIN NUMBER OF SHARES OFFERED
2,352
OFFERING TYPE
Equity
ASSET TYPE
PREFERRED
SHARES OFFERED
CF Convertible Preferred Stock
MAX NUMBER OF SHARES OFFERED
141,176

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

BioCurity Pharmaceuticals Inc.

Corporate Address

:

110 Front Street, Suite 300, Jupiter, FL 33477

Offering Minimum

:

$9,996.00

Offering Maximum

:

$599,998.00

Minimum Investment Amount

(per investor)

:

$510.00











Terms


Offering Type

:

Equity

Security Name

:

CF Convertible Preferred Stock

Minimum Number of Shares Offered

:

2,352

Maximum Number of Shares Offered

:

141,176

Price per Share

:

$4.25

Pre-Money Valuation

:

$34,019,537.00











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below

The 10% Bonus for StartEngine Shareholders

BioCurity Pharmaceuticals Inc. will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 or made at least two investments in StartEngine's own offerings.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of CF Convertible Preferred Stock at $4.25 / share, you will receive 110 CF Convertible Preferred Stock shares, meaning you'll own 110 shares for $425. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Salary payments made to one’s self, a friend or relative. Vendor payments. Any expense labeled “Travel and Entertainment”.

ALL UPDATES

06.13.20

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

05.19.20

BioCurity speaks with Dr. Clarence Brown, MD, about the lack of BioCurity's proprietary technology in the current environment, for cancer patients receiving radiation therapy


05.15.20

BioCurity receives a ‘Decision to Grant a Patent’ from the Japanese Patent Office (JPO) for their Proprietary Cerium Oxide Nanoparticle Radioprotectant

05.07.20

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

04.28.20

Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the BioCurity Pharmaceuticals Inc. offering. Here's an excerpt describing the specifics of the change:


BioCurity Pharmaceuticals Inc. has extended their campaign and updated 2019 financials.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

04.16.20

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

04.01.20

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

03.25.20

Is BioCurity's science truly "game-changing"? Just ask this Oncologist..


03.13.20

Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the BioCurity Pharmaceuticals Inc. offering. Here's an excerpt describing the specifics of the change:


BioCurity has extended their campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

03.04.20

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into BioCurity Pharmaceuticals Inc..

$1,003

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$390,048
INVESTORS
176
MIN INVEST
$510
VALUATION
$34.02M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.